New Amsterdam Partners’s Edwards Lifesciences EW Stock Holding History

New Amsterdam Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$297K	Sell	4,662 -2,238	-32%	-$128K	0.11%	95
2018 Q4	$352K	Sell	6,900 -72	-1%	-$3.64K	0.12%	92
2018 Q3	$405K	Sell	6,972 -702	-9%	-$34.3K	0.1%	93
2018 Q2	$372K	Sell	7,674 -4,827	-39%	-$225K	0.09%	99
2018 Q1	$581K	Buy	12,501 +4,260	+52%	+$185K	0.13%	97
2017 Q4	$310K	Sell	8,241 -462	-5%	-$17K	0.06%	107
2017 Q3	$317K	Buy	8,703 +654	+8%	+$24.9K	0.07%	109
2017 Q2	$317K	Buy	+8,049	New	+$294K	0.07%	110

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

New Amsterdam Partners's EW Position: Q1 2019 in Review

New Amsterdam Partners reduced its Edwards Lifesciences (EW) stake by 32% in Q1 2019, selling an estimated $128K and leaving 4,662 shares worth $297K. The position accounts for 0.11% of the portfolio, ranked #95.

New Amsterdam Partners first reported a position in EW in Q2 2017 and has held it in 8 quarters since. The position peaked at $581K in Q1 2018. 923 funds tracked by Wall St. Rank hold EW as of Q1 2019.

New Amsterdam Partners held 4,662 shares of Edwards Lifesciences worth $297K as of Q1 2019.
New Amsterdam Partners sold 2,238 Edwards Lifesciences shares in Q1 2019, an estimated $128K.
Edwards Lifesciences made up 0.11% of New Amsterdam Partners's portfolio in Q1 2019, its #95 holding.
New Amsterdam Partners first reported a position in Edwards Lifesciences in Q2 2017 and has held it in 8 quarters since.
New Amsterdam Partners's Edwards Lifesciences position peaked at $581K in Q1 2018.
923 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2019.

Based on New Amsterdam Partners's 13F filing for Q1 2019, filed 2 May 2019.